Drug intelligence / Profile preview

LY3114062

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

LY3114062 is a bispecific monoclonal antibody developed by Eli Lilly for the treatment of autoimmune diseases, particularly inflammatory arthritis. It functions as both an interleukin-17 (IL-17) inhibitor and a tumor necrosis factor alpha (TNF-α) inhibitor, targeting and modulating these two key pro-inflammatory cytokines involved in the pathogenesis of autoimmune and inflammatory conditions. The drug was investigated in phase 1 clinical trials to evaluate its safety and tolerability in patients with inflammatory arthritis. As of the latest updates, no further development beyond early clinical studies has been reported[1][2][4].

Targets

TNFA (Tumor necrosis factor alpha (soluble))IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on LY3114062.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3114062.

Explore the full profile